Literature DB >> 17650445

Monoclonal gammopathy: natural history studied with a retrospective approach.

Hlif Steingrimsdottir1, Vilhelmìna Haraldsdottir, Isleifur Olafsson, Vilmundur Gudnason, Helga M Ogmundsdottir.   

Abstract

The aim of this study was to examine the natural history of monoclonal gammopathy using a retrospective approach and a long observation period. Protein electrophoresis (PE) and immunofixation (IF) was performed on frozen prediagnosis serum samples from 65 multiple myeloma (MM) and 10 Waldenström's macroglobulinemia (WM) cases. Paraprotein was found in 28% and 46% of the samples from cases using PE and IF respectively. The type of paraprotein was IgA in 33.4% of cases, IgG in 57%, and IgM in 8.5%. Excluding light chain or non-secretory disease, 72 % of MM cases had a prodromal MGUS phase within 10 years of diagnosis MM and WM were preceded by MGUS in at least half of the cases, confirming the premalignant nature of this condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17650445     DOI: 10.3324/haematol.11284

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  3 in total

1.  Analyzing Relationship Between Monoclonal Gammopathy of Undetermined Significance (MGUS) with Different Types of Neuropathy: An Observational Study.

Authors:  Shahzaib Nabi; Pushpinderdeep Kahlon; Farshid Bozorgnia; Adeel Arshad; Akmam Saleem; Philip Kuriakose
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-28       Impact factor: 0.900

2.  Understanding the multiple biological aspects leading to myeloma.

Authors:  Eileen M Boyle; Faith E Davies; Xavier Leleu; Gareth J Morgan
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

3.  Community-acquired infections associated with increased risk of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia.

Authors:  Charlene M McShane; Liam J Murray; Eric A Engels; Lesley A Anderson
Journal:  Br J Haematol       Date:  2013-11-26       Impact factor: 6.998

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.